For tumor therapy, nucleic acid-based vaccines need to encode tumor-specific immunogenic peptides, which allows to comprise antigen-encoding sequences of different proteins within one minigene aimed to activate a broader number of CD4+ and CD8+ T cells [73]. This evidence concerns the gene CD8A and neoplasm.